Unknown

Dataset Information

0

Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.


ABSTRACT: ?-synuclein-induced neurotoxicity is a core pathogenic event in neurodegenerative synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. There is currently no disease-modifying therapy available for these diseases. We screened 1,600 FDA-approved drugs for their efficacy to protect LUHMES cells from degeneration induced by wild-type ?-synuclein and identified dipyridamole, a non-selective phosphodiesterase inhibitor, as top hit. Systematic analysis of other phosphodiesterase inhibitors identified a specific phosphodiesterase 1 inhibitor as most potent to rescue from ?-synuclein toxicity. Protection was mediated by an increase of cGMP and associated with the reduction of a specific ?-synuclein oligomeric species. RNA interference experiments confirmed PDE1A and to a smaller extent PDE1C as molecular targets accounting for the protective efficacy. PDE1 inhibition also rescued dopaminergic neurons from wild-type ?-synuclein induced degeneration in the substantia nigra of mice. In conclusion, this work identifies inhibition of PDE1A in particular as promising target for neuroprotective treatment of synucleinopathies.

SUBMITTER: Hollerhage M 

PROVIDER: S-EPMC5597612 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.

Höllerhage Matthias M   Moebius Claudia C   Melms Johannes J   Chiu Wei-Hua WH   Goebel Joachim N JN   Chakroun Tasnim T   Koeglsperger Thomas T   Oertel Wolfgang H WH   Rösler Thomas W TW   Bickle Marc M   Höglinger Günter U GU  

Scientific reports 20170913 1


α-synuclein-induced neurotoxicity is a core pathogenic event in neurodegenerative synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. There is currently no disease-modifying therapy available for these diseases. We screened 1,600 FDA-approved drugs for their efficacy to protect LUHMES cells from degeneration induced by wild-type α-synuclein and identified dipyridamole, a non-selective phosphodiesterase inhibitor, as top hit. Systematic analysis o  ...[more]

Similar Datasets

2017-10-01 | GSE87547 | GEO
| S-EPMC5702536 | biostudies-literature
| S-EPMC9037753 | biostudies-literature
| S-EPMC10883493 | biostudies-literature
| S-EPMC9167191 | biostudies-literature
2022-03-31 | GSE191302 | GEO
| S-EPMC9763379 | biostudies-literature
2023-04-06 | GSE226744 | GEO
| S-EPMC9291589 | biostudies-literature
| S-EPMC4280980 | biostudies-literature